PALMITIC ACID

Molecular Excipient

Mwt. LogP HBD HBA PSA RB CSP3
255.0 4.2 0 2 40.0 14 0.94
UNII
2V16EO95H1
CAS
57-10-3
SYNONYMS
  • Palmitic Acid
  • Hexadecanoic Acid
  • Cetylic Acid
  • N-Hexadecanoic Acid
  • Cetyl Acid
  • Fema No. 2832
  • Nsc-5030
  • Palmitic Acid [usan]
  • Palmitic Acid [ep]
  • Palmitic Acid [mart.]
  • Palmitic Acid [mi]
  • Palmitic Acid [inci]
  • Palmitic Acid [fhfi]
  • Palmitic Acid [fcc]
  • Palmitic Acid [ii]
  • Palmitic Acid [hsdb]
  • 1-Pentadecanecarboxylic Acid
  • Palmitic Acid [usp-Rs]
  • Palmitic Acid [who-Dd]
  • Cetyl Acid [vandf]
  • Palmitic Acid [vandf]
  • Edenor C 16-98-100
  • Hydrofol Acid 1690
  • Imex C 1498
  • Kortacid 1698
  • Loxiol Ep 278
  • Prifac-2960
  • Pristerene-4934
  • Palmitic Acid (constituent Of Evening Primrose Oil) [dsc]
  • Palmitic Acid (constituent Of Flax Seed Oil) [dsc]
  • Palmitic Acid [dsc]
  • Palmitic Acid (constituent Of Saw Palmetto) [dsc]
  • Palmitic Acid (constituent Of Spirulina) [dsc]
  • Palmitic Acid (constituent Of Borage Seed Oil) [dsc]
ZINC ID(s)
Availability
Present in 83 ZINC catalogs

Known Active Genes

This compound has been observed to have activity at 10μM or less against the following gene(s).
Name Description Classification
FABP2 Fatty acid-binding protein, intestinal Auxiliary Transport Protein / Atp-Fabp
FABP3 Fatty acid-binding protein, heart Auxiliary Transport Protein / Atp-Fabp
FABP5 Fatty acid-binding protein, epidermal Auxiliary Transport Protein / Atp-Fabp
FABP4 Fatty acid-binding protein, adipocyte Auxiliary Transport Protein / Atp-Fabp
TLR2 Toll-like receptor 2 Membrane Receptor / Membrane-Other
PPARD Peroxisome proliferator-activated receptor delta Unclassified / Unclassified
PPARA Peroxisome proliferator-activated receptor alpha Transcription Factor / Nr

Clinical Trials

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
Code Date Title Phase Status
NCT02146547 2015-02-01 European Long-acting Antipsychotics in Schizophrenia Trial Phase 4 Not Yet Recruiting
NCT01947803 2013-09-01 A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia Phase 4 Active, Not Recruiting
NCT01795547 2013-02-01 Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia Phase 3 Completed
NCT01685931 2012-11-01 A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics Phase 4 Active, Not Recruiting
NCT01458379 2012-08-01 Brain Myelination Effects of Paliperidone Palmitate Versus Oral Risperidone in First Episode Schizophrenia Phase 4 Not Yet Recruiting
NCT01527305 2012-06-01 A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia Phase 4 Completed
NCT01682161 2012-01-01 A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate Phase 4 Completed
NCT01476358 2011-11-01 Effect of Vitamin A Supplementation on Immune Responses in Human Neonates Phase 2 Active, Not Recruiting
NCT01451736 2011-10-01 Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia Phase 4 Recruiting
NCT01448720 2011-09-01 Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate Phase 3 Completed
NCT01860781 2011-08-01 The Effect of Paliperidone Palmitate in Schizophrenia Phase 4 Recruiting
NCT01381276 2011-06-01 Vitamin A Absorption From Cassava in Women Phase 2 Completed
NCT01362426 2011-03-01 Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL) Phase 4 Completed
NCT01136772 2011-02-01 A Comparison of Long-acting Injectable Medications for Schizophrenia Phase 4 Active, Not Recruiting
NCT01281527 2010-11-01 Paliperidone Palmitate Flexible Dosing in Schizophrenia Phase 3 Completed
NCT01299389 2010-10-01 An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia Phase 3 Completed
NCT01211704 2010-10-01 Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism Phase 4 Withdrawn
NCT01258920 2010-10-01 A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia Phase 3 Completed
NCT01193153 2010-09-01 A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder Phase 3 Completed
NCT01181960 2010-08-01 Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations Phase 4 Completed
NCT01193166 2010-08-01 Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital Phase 4 Withdrawn
NCT01157351 2010-05-01 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated Phase 4 Completed
NCT01051531 2010-04-01 A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia Phase 3 Completed
NCT01081769 2010-02-01 Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics Phase 3 Completed
NCT00946985 2009-06-01 28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years Phase 4 Terminated
NCT01942382 2009-04-01 A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia Phase 1 Completed
NCT01559272 2008-02-01 A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia Phase 1 Completed
NCT00604279 2008-01-01 A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia Phase 3 Completed
NCT01150448 2007-09-01 A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia Phase 1 Completed
NCT00589914 2007-03-01 Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia Phase 3 Completed
NCT00590577 2007-03-01 Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia Phase 3 Completed
NCT01606254 2007-01-01 A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia Phase 2 Completed
NCT00862368 2005-10-01 Sustaining Smoking Cessation in Smokers With Kids With Asthma Phase 3 Completed
NCT01110317 2005-07-01 A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate Phase 1 Completed
NCT00119756 2005-06-01 A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia Phase 3 Completed
NCT00210548 2005-04-01 A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia Phase 3 Completed
NCT00111189 2005-02-01 A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia. Phase 3 Completed
NCT00210717 2005-02-01 A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia Phase 3 Completed
NCT00101634 2004-12-01 Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia Phase 3 Completed
NCT00073320 2003-08-01 Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia Phase 3 Completed
NCT00198718 1997-11-01 Single-dose Postpartum Vitamin A Supplementation of Mothers and Neonates Phase 2 Active, Not Recruiting

(Browse) Purchasable Analogs in ZINC

Dosages

Route Formulation Per Unit Dose
Intravenous Injection, Suspension 0.001%
Oral Tablet 6MG

More Information

Usage Over Time

Comments